Do you have renal cell cancer that has spread beyond your kidney and surgery is not recommended? You may be able to take part in a research study to help us learn if adding radiation therapy to your usual cancer treatment may help your cancer shrink.

Are you affiliated with a federal and/or state-recognized tribe and between the ages of 18-25? We want to learn about physical activity practices in the college-age Native American Community. Take our 30-minute survey answering questions about your environment, how your culture promotes physical activity, your access to physical activity, and what you do for physical activity.

The purpose of this research study is to test if researchers can create personalized stem cells from the skin of ovarian cancer patients and see if these cells can attack cancer cells. Stem cell therapy is a promising approach to treating ovarian cancer.

Have you been diagnosed with breast cancer with brain metastases? If so, you may be able to take part in a research study looking at the safety of giving a new drug called olaparib concurrently (at the same time) with stereotactic radiosurgery to patients with breast cancer with brain metastases.

Have you been diagnosed with metastatic brain cancer (tumor)? If so, you may be able to take part in a research study looking at the safety of giving radiation therapy through a device called GammaTiles™ to patients with newly diagnosed metastatic brain tumors planned for surgical resection.

Have you been diagnosed with Leukemia? You may be able to take part in a research study to find out if a new study drug can help put your blood cancer into remission.

Are you a patient with locally advanced or metastatic squamous cell carcinoma? If so, you may be eligible to participate in a clinical research study involving an investigational drug, NBTXR3.

Do you have lupus? We want to learn if Mycophenolate Mofetil (MMF) and voclospoporin medications used in this study are the same or better at treating lupus outside the kidney (SLE)

Can we increase the clinical complete response rate (tumor disappears by exam, endoscopy, and imaging) by adding a 3rd drug (irinotecan) to the standard regimen of FOLFOX or CAPOX given following long-course chemoradiation for patients with locally advanced rectal cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your rectal cancer. The usual approach is defined as care most people get for locally advanced rectal cancer.

Do you have newly-diagnosed multiple myeloma? If so, you may be able to participate in a research study looking at the safety, efficacy, and tolerability of giving isatuximab in combination with lenalidomide and dexamethasone at lower doses.